<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39391153</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>JN.1: enhanced immune evasion ability propels it to become the predominant strain in China, unlikely to trigger pandemic similar to late 2022.</ArticleTitle><Pagination><StartPage>1442291</StartPage><MedlinePgn>1442291</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1442291</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2024.1442291</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Due to the widespread presence of susceptible populations, the pandemic caused by BA.5 subbranches swiftly disseminated China, impacting the majority of individuals within a span of 1 to 2 months. Subsequently, XBB and its subbranches became the dominant variants in China.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We tracked the immune landscape in the population after the SARS-CoV-2 pandemic in late 2022 in China.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our findings suggested that low levels of neutralizing antibodies against BA.5 subbranches before the pandemic might have contributed to the national outbreak at the end of 2022. The widespread breakthrough infections subsequently increased immunity to BA.5, XBB.1.5/1.9.1, and JN.1, inhibiting a new wave of large-scale infections caused by XBB subbranches in China. Additionally, JN.1 demonstrated enhanced immune evasion capabilities; however, Chinese residents had comparable levels of neutralizing antibodies against JN.1 as those observed for XBB.1.5 among confirmed cases at the end of 2022.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">We anticipate that JN.1 will replace XBB subbranches as the predominant epidemic variant in subsequent transmissions within China. However, it is unlikely to cause a large-scale spread comparable to that witnessed at the end of 2022, with transmission patterns potentially resembling those observed for XBB post-pandemic.</AbstractText><CopyrightInformation>Copyright © 2024 Du, Li, Wei, Guo and Li.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Macau University of Science and Technology, Macao SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Meiyi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Guohui</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Chengbin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Macau University of Science and Technology, Macao SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="Y">Immune Evasion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">China</Keyword><Keyword MajorTopicYN="N">JN.1</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immune evasion</Keyword><Keyword MajorTopicYN="N">neutralization</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39391153</ArticleId><ArticleId IdType="pmc">PMC11464334</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2024.1442291</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu J, Liu M, Liang W. The dynamic Covid-zero strategy in China. China CDC Wkly. (2022) 4:74–5. doi: 10.46234/ccdcw2022.015</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2022.015</ArticleId><ArticleId IdType="pmc">PMC8837441</ArticleId><ArticleId IdType="pubmed">35186372</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitiello A, Ferrara F, Auti AM, Di Domenico M, Boccellino M. Advances in the omicron variant development. J Intern Med. (2022) 292:81–90. doi: 10.1111/joim.13478</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13478</ArticleId><ArticleId IdType="pmc">PMC9115048</ArticleId><ArticleId IdType="pubmed">35289434</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y, Wang L, Feng Z, Xu H, Li F, Shen Y, et al. . Characterisation of Sars-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet. (2023) 401:664–72. doi: 10.1016/S0140-6736(23)00129-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00129-0</ArticleId><ArticleId IdType="pmc">PMC9949854</ArticleId><ArticleId IdType="pubmed">36773619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Yu Y, Jian F, Song W, Yisimayi A, Chen X, et al. . Antigenicity and infectivity characterisation of Sars-CoV-2 Ba.2.86. Lancet Infect Dis. (2023) 23:e457–9. doi: 10.1016/S1473-3099(23)00573-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00573-X</ArticleId><ArticleId IdType="pubmed">37738994</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheward DJ, Yang Y, Westerberg M, Öling S, Muschiol S, Sato K, et al. . Sensitivity of the Sars-CoV-2 Ba.2.86 variant to prevailing neutralising antibody responses. Lancet Infect Dis. (2023) 23:e462–3. doi: 10.1016/S1473-3099(23)00588-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00588-1</ArticleId><ArticleId IdType="pubmed">37776877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, et al. . Antigenicity and receptor affinity of Sars-CoV-2 Ba.2.86 spike. Nature. (2023) 624:639–44. doi: 10.1038/s41586-023-06750-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06750-w</ArticleId><ArticleId IdType="pubmed">37871613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassauni R, Polacek C, Utko M, Sørensen KM, Baig S, Ellegaard K, et al. . Virus isolation and neutralisation of Sars-CoV-2 variants Ba.2.86 and Eg.5.1. Lancet Infect Dis. (2023) 23:e509–10. doi: 10.1016/S1473-3099(23)00682-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00682-5</ArticleId><ArticleId IdType="pubmed">37949089</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan K, Lustig G, Römer C, Reedoy K, Jule Z, Karim F, et al. . Evolution and neutralization escape of the Sars-CoV-2 Ba.2.86 subvariant. Nat Commun. (2023) 14:8078. doi: 10.1038/s41467-023-43703-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43703-3</ArticleId><ArticleId IdType="pmc">PMC10700484</ArticleId><ArticleId IdType="pubmed">38057313</ArticleId></ArticleIdList></Reference><Reference><Citation>Uriu K, Ito J, Kosugi Y, Tanaka YL, Mugita Y, Guo Z, et al. . Transmissibility, infectivity, and immune evasion of the Sars-CoV-2 Ba.2.86 variant. Lancet Infect Dis. (2023) 23:e460–1. doi: 10.1016/S1473-3099(23)00575-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00575-3</ArticleId><ArticleId IdType="pubmed">37734391</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, et al. . Fast evolution of Sars-CoV-2 Ba.2.86 to Jn.1 under heavy immune pressure. Lancet Infect Dis. (2024) 24:e70–2. doi: 10.1016/S1473-3099(23)00744-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00744-2</ArticleId><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. Overview of neutralizing antibodies and their potential in Covid-19. Vaccine. (2021) 9:1376. doi: 10.3390/vaccines9121376</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9121376</ArticleId><ArticleId IdType="pmc">PMC8706198</ArticleId><ArticleId IdType="pubmed">34960121</ArticleId></ArticleIdList></Reference><Reference><Citation>Abebe EC, Dejenie TA. Protective roles and protective mechanisms of neutralizing antibodies against Sars-CoV-2 infection and their potential clinical implications. Front Immunol. (2023) 14:1055457. doi: 10.3389/fimmu.2023.1055457</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1055457</ArticleId><ArticleId IdType="pmc">PMC9892939</ArticleId><ArticleId IdType="pubmed">36742320</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to Sars-CoV-2 infection by mass vaccination. Lancet. (2020) 396:1614–6. doi: 10.1016/S0140-6736(20)32318-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32318-7</ArticleId><ArticleId IdType="pmc">PMC7836302</ArticleId><ArticleId IdType="pubmed">33159850</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Du P, Yu M, Baptista-Hon DT, Miao M, Xiang AP, et al. . Assessment of infectivity and the impact on neutralizing activity of immune sera of the Covid-19 variant, Cal.20C. Signal Transduct Target Ther. (2021) 6:285. doi: 10.1038/s41392-021-00695-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00695-0</ArticleId><ArticleId IdType="pmc">PMC8313410</ArticleId><ArticleId IdType="pubmed">34315848</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Zhou Z, Du P, Yu M, Li N, Xiong X, et al. . The Sars-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera. Precis Clin Med. (2021) 4:149–54. doi: 10.1093/pcmedi/pbab016, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pcmedi/pbab016</ArticleId><ArticleId IdType="pmc">PMC8385834</ArticleId><ArticleId IdType="pubmed">35693215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Du P, Li N, Xiong X, Tang S, Dai Q, et al. . Homologous or heterogenous vaccination boosters enhance neutralizing activities against Sars-CoV-2 omicron Ba.1 variant. MedComm (2020). (2022) 3:e143. doi: 10.1002/mco2.143, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.143</ArticleId><ArticleId IdType="pmc">PMC9095991</ArticleId><ArticleId IdType="pubmed">35592756</ArticleId></ArticleIdList></Reference><Reference><Citation>Du P, Li N, Xiong X, Tang S, Dai Q, Liu Z, et al. . A bivalent vaccine containing D614G and Ba.1 spike trimer proteins or a Ba.1 spike trimer protein booster shows broad neutralizing immunity. J Med Virol. (2022) 94:4287–93. doi: 10.1002/jmv.27885, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27885</ArticleId><ArticleId IdType="pubmed">35614524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. . Quantification of Sars-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. (2020) 15:3699–715. doi: 10.1038/s41596-020-0394-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0394-5</ArticleId><ArticleId IdType="pubmed">32978602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Gao GF. No novel prevalent mutations detected in the circulating strains of bf.7, Ba.5.2, Dy, and Xbb-China, November 2022 to June 2023. China CDC Wkly. (2023) 5:672–3. doi: 10.46234/ccdcw2023.126</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2023.126</ArticleId><ArticleId IdType="pmc">PMC10427496</ArticleId><ArticleId IdType="pubmed">37593125</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R, Zhang Y, Ma J, Wang H, Lan Y, Tang X. Epidemiological features of Sars-CoV-2 omicron infection under new control strategy: a cross-sectional study of the outbreak since December 2022 in Sichuan, China. BMC Public Health. (2023) 23:2463. doi: 10.1186/s12889-023-17361-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-023-17361-5</ArticleId><ArticleId IdType="pmc">PMC10709916</ArticleId><ArticleId IdType="pubmed">38066518</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung K, Lau EHY, Wong CKH, Leung GM, Wu JT, et al. . Estimating the transmission dynamics of Sars-CoV-2 omicron bf.7 in Beijing after adjustment of the zero-Covid policy in November-December 2022. Nat Med. (2023) 29:579–82. doi: 10.1038/s41591-023-02212-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02212-y</ArticleId><ArticleId IdType="pubmed">36638825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Peng Z, Wei F, Jin Z, Wang J, Xu X, et al. . Study on the Covid-19 epidemic in mainland China between November 2022 and January 2023, with prediction of its tendency. J Biosaf Biosecur. (2023) 5:39–44. doi: 10.1016/j.jobb.2023.03.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jobb.2023.03.001</ArticleId><ArticleId IdType="pmc">PMC10030260</ArticleId><ArticleId IdType="pubmed">36992708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Niu P, Su Q, He X, Tang J, Wang J, et al. . Genomic surveillance for Sars-CoV-2- China, September 26, 2022 to January 29, 2023. China CDC Wkly. (2023) 5:143–51. doi: 10.46234/ccdcw2023.026, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2023.026</ArticleId><ArticleId IdType="pmc">PMC10061763</ArticleId><ArticleId IdType="pubmed">37009519</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. . Duration of effectiveness of vaccines against Sars-CoV-2 infection and Covid-19 disease: results of a systematic review and meta-regression. Lancet. (2022) 399:924–44. doi: 10.1016/S0140-6736(22)00152-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. Coronavirus variant XBB.1.5 rises in the United States – is it a global threat? Nature. (2023) 613:222–3. doi: 10.1038/d41586-023-00014-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-00014-3</ArticleId><ArticleId IdType="pubmed">36624320</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al. . Alarming antibody evasion properties of rising Sars-CoV-2 Bq and Xbb subvariants. Cell. (2023) 186:279–86.e8. doi: 10.1016/j.cell.2022.12.018, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.12.018</ArticleId><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Yisimayi A, Song W, Wang J, Jian F, Yu Y, Chen X, et al. . Repeated omicron exposures override ancestral Sars-CoV-2 immune imprinting. Nature. (2024) 625:148–56. doi: 10.1038/s41586-023-06753-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06753-7</ArticleId><ArticleId IdType="pmc">PMC10764275</ArticleId><ArticleId IdType="pubmed">37993710</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>